| Title: | Inhibition of AMP-Activated Protein Kinase at the Allosteric Drug-Binding Site Promotes Islet Insulin Release |
| Authors: | Kemp, BE Steinberg, GR Birnberg, NC Kay, TW Thomas, HE Weng, QP Langendorf, CG Issa, SMA Dite, TA Ling, NXY Foitzik, R Graham, KL Galic, S Scott, JW Oakhill, JS |
| Issue Year: | 2015 |
| Publisher | |
| Series | Chem Biol: |
| Abstract | The AMP-activated protein kinase (AMPK) is a metabolic stress-sensing αβγ heterotrimer responsible for energy homeostasis. Pharmacological inhibition of AMPK is regarded as a therapeutic strategy in some disease settings including obesity and cancer; however, the broadly used direct AMPK inhibitor compound C suffers from poor selectivity. We have discovered a dihydroxyquinoline drug (MT47-100) with novel AMPK regulatory properties, being simultaneously a direct activator and inhibitor of AMPK complexes containing the β1 or β2 isoform, respectively. Allosteric inhibition by MT47-100 was dependent on the β2 carbohydrate-binding module (CBM) and determined by three non-conserved CBM residues (Ile81, Phe91, Ile92), but was independent of β2-Ser108 phosphorylation. Whereas MT47-100 regulation of total cellular AMPK activity was determined by β1/β2 expression ratio, MT47-100 augmented glucose-stimulated insulin secretion from isolated mouse pancreatic islets via a β2-dependent mechanism. Our findings highlight the therapeutic potential of isoform-specific AMPK allosteric inhibitors. |
| URI: | https://publications.svi.edu.au/publications/2441 |
| Other Identifiers | |
| Publication type | Article |
| Grant ID | GNT1037321; GNT1042735 |